MedTrace Logo

Fulvestrant in Postmenopausal Patients With Metastatic Breast Cancer

NCT01399086 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 140

Last updated 2012-03-13

No results posted yet for this study

Summary

This is a retrospective chart-review study that will be based on the collection of data from electronical or paper-based medical records with available data on patients who have commenced treatment with fulvestrant after January 1st of 2007. All necessary information for the purposes of the present study will be collected with the use of a paper-Case Record Form.

Conditions

Interventions

DRUG

Fulvestrant

250mg on d1,15,29 or 250mg on d1 q28days

Sponsors & Collaborators

  • Hellenic Oncology Research Group

    lead OTHER

Principal Investigators

  • Vassilis Georgoulias, MD · University Hospital of Crete, Dep of Medical Oncology

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01399086 on ClinicalTrials.gov